振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300158 振东制药

已收盘 04-30 15:00:00

{"stockData":{"symbol":"300158","market":"SZ","secType":"STK","nameCN":"振东制药","latestPrice":4.7,"timestamp":1714460622000,"preClose":4.62,"halted":0,"volume":26650800,"delay":0,"floatShares":1024000000,"shares":1027000000,"eps":-0.02,"marketStatus":"已收盘","marketStatusCode":5,"change":0.08,"latestTime":"04-30 15:00:00","open":4.66,"high":4.73,"low":4.61,"amount":125000000,"amplitude":0.026,"askPrice":4.7,"askSize":5144,"bidPrice":4.69,"bidSize":1616,"shortable":0,"etf":0,"ttmEps":-0.02,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":4.62,"symbolType":"stock","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":5.08,"lowLimit":4.16,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1027494660,"pbRate":0.93,"roa":"--","roe":"0.45%","epsLYR":-0.0428,"committee":-0.350438,"marketValue":4829000000,"floatMarketCap":4813000000,"peRate":-235.000005,"changeRate":0.0173,"turnoverRate":0.026,"status":0},"requestUrl":"/m/hq/s/300158","defaultTab":"news","newsList":[{"id":"2431786524","title":"振东制药（300158）股东山西振东健康产业集团有限公司质押1105万股，占总股本1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431786524","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431786524?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:36","pubTimestamp":1714397799,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药4月29日公开信息显示，股东山西振东健康产业集团有限公司向中国银行股份有限公司长治市分行合计质押1105.0万股，占总股本1.08%。质押详情见下表：截止本公告日，股东山西振东健康产业集团有限公司已累计质押股份1.81亿股，占其持股总数的59.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900032444.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429124178","title":"振东制药（300158）4月23日主力资金净买入808.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429124178","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429124178?lang=zh_cn&edition=full","pubTime":"2024-04-24 09:15","pubTimestamp":1713921327,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月23日收盘，振东制药报收于4.34元，上涨4.33%，换手率3.35%，成交量34.27万手，成交额1.48亿元。近5日资金流向一览见下表：振东制药融资融券信息显示，融资方面，当日融资买入716.6万元，融资偿还616.69万元，融资净买入99.91万元。振东制药主营业务：肿瘤、毛发、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400018343.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429974208","title":"图解振东制药一季报：第一季度单季净利润同比增5952.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429974208","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429974208?lang=zh_cn&edition=full","pubTime":"2024-04-23 01:37","pubTimestamp":1713807426,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药2024年一季报显示，公司主营收入7.82亿元，同比下降17.79%；归母净利润2310.16万元，同比上升5952.52%；扣非净利润-859.24万元，同比上升51.35%；负债率15.08%，投资收益1688.88万元，财务费用-44.9万元，毛利率44.39%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300002122.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429949065","title":"振东制药最新公告：一季度净利润2310.16万元 同比扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2429949065","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429949065?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:40","pubTimestamp":1713782453,"startTime":"0","endTime":"0","summary":"振东制药公布2024年一季度报告，报告期营业收入7.82亿元，同比下降17.79%；归属于上市公司股东的净利润2310.16万元，同比扭亏为盈。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200022334.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429011945","title":"振东制药(300158.SZ)发布一季度业绩，净利润2310.16万元，扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2429011945","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429011945?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:14","pubTimestamp":1713780895,"startTime":"0","endTime":"0","summary":"智通财经APP讯，振东制药(300158.SZ)发布2024年第一季度报告，公司营业收入7.82亿元，同比下降17.79%;归属于上市公司股东的净利润2310.16万元，扭亏为盈;归属于上市公司股东的扣除非经常性损益的净亏损859.24万元，亏损收窄;基本每股收益0.0225元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106647.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429945715","title":"振东制药(300158.SZ)发布2023年度业绩，净亏损4398.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429945715","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429945715?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:12","pubTimestamp":1713780753,"startTime":"0","endTime":"0","summary":"智通财经APP讯，振东制药(300158.SZ)发布2023年年度报告，报告期内，公司实现营业收入36.26亿元，同比下降2.75%。归属于上市公司股东的净亏损4398.41万元，归属于上市公司股东的扣除非经常性损益的净亏损1.16亿元，基本每股亏损0.0428元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106645.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429452499","title":"振东制药(300158.SZ)聘任刘永森为财务总监","url":"https://stock-news.laohu8.com/highlight/detail?id=2429452499","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429452499?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:12","pubTimestamp":1713780723,"startTime":"0","endTime":"0","summary":"智通财经APP讯，振东制药(300158.SZ)公告，公司董事会近日收到公司财务总监刘长禄的书面辞职报告。刘长禄因个人原因申请辞去公司财务总监职务，辞职后在公司担任其他职务。公司董事会同意聘任刘永森为公司财务总监，任期自本次会议审议通过之日起至第五届董事会任期届满之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106644.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429438945","title":"振东制药(300158.SZ)选举董事李昆担任董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2429438945","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429438945?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:09","pubTimestamp":1713780574,"startTime":"0","endTime":"0","summary":"智通财经APP讯，振东制药(300158.SZ)公告，公司董事会近日收到公司董事长李安平的书面辞职报告。李安平因个人原因辞去公司第五届董事会董事长及董事会战略与发展委员会召集人、董事会提名委员会委员职务，辞职后将不再担任公司任何职务。公司董事会选举公司董事李昆担任公司第五届董事会董事长，任期自本次董事会审议通过之日起至第五届董事会届满之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106641.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424129438","title":"振东制药(300158.SZ)已耗资8422.51万元回购1.75%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2424129438","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2424129438?lang=zh_cn&edition=full","pubTime":"2024-04-03 20:01","pubTimestamp":1712145660,"startTime":"0","endTime":"0","summary":"振东制药(300158.SZ)发布公告，截至2024年3月31日，公司通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份1796.54万股，占公司总股本的1.75%，最高成交价为5.10元/股，最低成交价为4.31元/股，成交总金额为人民币8422.51万元(不含交易费用)。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-03/doc-inaqqitq2687453.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-03/doc-inaqqitq2687453.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417377517","title":"股权质押和资金占用  振东制药几大问题显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2417377517","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2417377517?lang=zh_cn&edition=full","pubTime":"2024-03-08 10:31","pubTimestamp":1709865060,"startTime":"0","endTime":"0","summary":"　　近期，振东制药公告股东质押股份，涉及控股方和实控人。不过，2022年起公司陷入亏损，何时扭亏为盈成为市场关心的话题。同时，控股方与公司的各种往来交易，也受到监管层注意。截至今年上半年，李安平直接持有公司0.23%的表决权，且拥有振东集团99.9%的表决权，从而间接拥有公司29.38%的表决权。实际上，公司关联方的资金占用已有先例。　　2023年前三季度，公司销售费用10.73亿元，同比降低5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-03-08/doc-inamqmiu2446275.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-03-08/doc-inamqmiu2446275.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2408221625","title":"概念掘金 | 国产创新药再突破，这股飙涨逾40%！千亿脱发赛道风云渐起","url":"https://stock-news.laohu8.com/highlight/detail?id=2408221625","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2408221625?lang=zh_cn&edition=full","pubTime":"2024-02-02 14:32","pubTimestamp":1706855535,"startTime":"0","endTime":"0","summary":"一根头发牵动的千亿蓝海","market":"sg","thumbnail":"https://img3.gelonghui.com/7e773-10c4284c-8fbd-463e-92d7-83656e518ff9.jpg?guru_height=855&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/7e773-10c4284c-8fbd-463e-92d7-83656e518ff9.jpg?guru_height=855&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/691201","is_publish_highlight":false,"gpt_icon":0},{"id":"2400350273","title":"振东制药回应“王俊凯起诉”：与上市公司无关，相关方已达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2400350273","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2400350273?lang=zh_cn&edition=full","pubTime":"2024-01-04 17:40","pubTimestamp":1704361200,"startTime":"0","endTime":"0","summary":"近日，中国庭审公开网发布一则庭审预告，案由为肖像权纠纷，原告为王俊凯，被告为贵州一品药业连锁有限公司五百零一分店、山西振东安欣生物制药有限公司、山西振东制药股份有限公司、夏江。该案将于1月8日上午在贵阳市白云区人民法院开庭审理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-01-04/doc-inaakawx6075387.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-01-04/doc-inaakawx6075387.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-01-07","address":"山西省长治市上党区光明南路振东科技园","stockEarnings":[{"period":"1week","weight":0.0829},{"period":"1month","weight":-0.0208},{"period":"3month","weight":0.0375},{"period":"6month","weight":-0.2587},{"period":"1year","weight":-0.2257},{"period":"ytd","weight":-0.3037}],"companyName":"山西振东制药股份有限公司","boardCode":"AI0027","perCapita":"19032股","boardName":"医药制造业","registeredCapital":"102749万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":"　　山西振东制药股份有限公司肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售，以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品为消化系统药、呼吸系统类用药、泌尿系统药、心脑血管药、抗肿瘤药、血液造血系统药、补益药、抗感染药、皮肤病用药。2022年全国医药工业信息年会公布2021年度全国医药工业百强榜，公司位列第64位。2023年米思会上发布的2022年度中国化药企业TOP100排行榜中，公司位列第52位。公司在2022-2023年度中国医药行业最具影响力榜单评选中获得“医药制造业百强”称号。公司技术中心在2022年被认定为“国家企业中心”，是山西省2022年唯一通过国家认定的企业技术中心。","serverTime":1714796700163,"listedPrice":38.8,"stockholders":"53808人(较上一季度增加0.34%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"振东制药,300158,振东制药股票,振东制药股票老虎,振东制药股票老虎国际,振东制药行情,振东制药股票行情,振东制药股价,振东制药股市,振东制药股票价格,振东制药股票交易,振东制药股票购买,振东制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}